Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$-0.73
EPS est.
$-0.81
EPS surprise
+9.65%
1-day move
+2.92%
Rhythm Pharmaceuticals reported better-than-expected earnings per share, which contributed to a positive stock reaction, with shares rising by 2.92%. However, the company did not provide revenue figures or guidance, leaving investors without a complete picture of future performance. The positive EPS surprise may indicate better cost management or operational efficiency.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.73 | $-0.83 | +9.65% |
| Revenue | — | $68M | — |
No transcript is on record for this earnings call, so the analysis is based solely on numerical results.
Rhythm Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative treatments for rare genetic disorders related to obesity. With a market cap of $8 billion, the company plays a significant role in the health care sector, particularly as it addresses unmet medical needs in a growing market.
Last quarter
In Q1-2026, Rhythm Pharmaceuticals reported an EPS of -$0.83, slightly better than the expected -$0.86, resulting in a positive stock reaction of 7.86% the following day. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.
EPS beat streak
3Q
EPS beat rate
50%
Avg EPS surprise
-3.02%
Avg 1-day reaction
+1.73%
Analysts expect Rhythm Pharmaceuticals to report a loss of $0.83 per share on $68 million in revenue for Q2-2026. The market is closely watching how the company manages its costs and revenue growth.
Bull case
If Rhythm can exceed revenue expectations and show signs of improving profitability, it could lead to a strong positive reaction in the stock price, reflecting investor confidence.
Bear case
Conversely, if the company fails to meet the EPS and revenue estimates, it may trigger a sell-off, as investors could lose faith in the company's growth trajectory.
Key metrics to watch
EPS
-$0.83Earnings per share (EPS) is a key indicator of the company's profitability and financial health.
Revenue
$68MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the company meet or exceed the consensus revenue estimate of $68 million?
Revenue performance is critical for assessing the company's growth and market acceptance of its products.
Q2
How will management address the ongoing losses indicated by the expected EPS of -$0.83?
Investors will be keen to hear about strategies for improving profitability and managing costs.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be underestimating the potential for revenue growth driven by recent product launches, which could lead to better-than-expected sales.
Supporting evidence
The options market is pricing in a significant move, indicating that traders anticipate volatility, which may not align with consensus expectations.
Rhythm's recent product developments could attract more market interest than analysts currently project.
Key risk
If revenue comes in significantly above $68 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's results are pivotal in determining the company's trajectory amidst ongoing losses and market expectations.
Bull confirmed if
Exceeding the revenue estimate of $68 million and showing a path to profitability would confirm the bull case.
Bear confirmed if
Falling short of the EPS estimate of -$0.83 and providing no clear strategy for improvement would confirm the bear case.
What the market is pricing for the move.
Implied Move
±11.61%
Historical Avg
±4.4%
The options market is pricing in a significant move of about 11.61%, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±11.6% while RYTM has averaged ±4.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
50.6%
Smart-money positioning from the most recent 13F filings.
Institutional
114.84%
of float
Insider
0.70%
of float
Holders
428
institutions
Top Holders· as of Jun 2026
RA Capital Management, L.P.
6,666,837 sh · $589.7M
9.73%
Flat
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Rhythm beats expectations, history suggests a potential stock increase of around 3.24%, confirming positive investor sentiment.
In line / cautious
An in-line report may lead to a muted reaction, as investors await further guidance from management.
Miss
If the company misses expectations, history suggests a potential decline of around 0.50%, reflecting investor disappointment.
The lines on the call that would change the story.
Blackrock Inc.
6,156,902 sh · $544.6M
8.98%
-1.3%
Baker Bros. Advisors, LP
5,604,483 sh · $495.7M
8.18%
Flat
Primecap Management Company
3,168,853 sh · $280.3M
4.62%
-7.3%
Vanguard Portfolio Management LLC
3,136,895 sh · $277.5M
4.58%
3.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.